































	 Microwave	 assisted	 and	 conventional	 synthetic	 methods	 of	 new	 6‐bromo‐2‐(substituted)‐3H‐imidazo[4,5‐b]pyridine	 and	 its	 derivatives	 are	 described,	 which	 were	 obtained	 in
reduced	reaction	times,	higher	yields,	cleaner	reactions	than	previously	described	methods.
All	 the	 synthesized	 compounds	were	 characterized,	 and	 screened	 for	 their	 anticancer	 and
antimicrobial	 activity.	 Among	 synthesized	 compounds	 3b	 and	 3k	 shows	 prominent
antibacterial	 activity	 and	 compound	 3f	 shows	 both	 antibacterial	 and	 antifungal	 activity.
Compounds	 3h	 and	 3j	 shows	prominent	 anticancer	 activity	 against	 the	both	 breast	 cancer














Infections	 caused	 by	multi‐drug	 resistant	 bacteria	 are	 of	
major	 health	 concern	 worldwide.	 The	 imidazole	 and	
benzimidazole	 nucleus	 are	 important	 building	 blocks	 in	 the	
drug	discovery.	The	imidazole	ring	system	is	considered	to	be	
one	of	the	most	imperative	heterocyclic	substructures	found	in	
a	 large	 number	 of	 natural	 products	 and	 pharmacologically	
active	compounds.	An	examination	of	 literature	revealed	 that	
imidazole	 and	 their	 analogues	 usually	 possess	 diverse	
biological	 activities	 like	 antimicrobial,	 antioxidant,	 antihe‐
molytic,	 cytotoxic	 [1]	and	antimycobacterial	 [2].	Almost	all	of	
the	major	classes	of	antibiotics	have	encountered	resistance	in	
clinical	 applications	 [3].	 Because	 of	 the	 versatile	 core	
contained	 in	 several	 substances	 of	 imidazole	 derivatives	 are	
possess	 a	 broad	 spectrum	of	 pharmacological	 activities	 [4,5].	
Recently	imidazole	and	its	derivatives	has	been	the	subject	of	
extensive	study	of	the	antimicrobial	activity	for	their	potential	
as	 effective	 therapeutic	 agents.	 Based	 on	 several	 literature	
surveys,	 imidazole	 derivatives	 show	 a	 range	 of	 pharma‐
cological	 activities,	 such	 as	 antimicrobial,	 anti‐tubercular,	
antiviral	 [6‐11],	 antioxidant	 and	 antifungal	 [12],	 antidepres‐
sant	 [13],	anti‐inflammatory	and	analgesic	 [14],	anti‐tubercu‐
losis	[15]	anticancer	[16,17].	The	imidazole	scaffold	is	present	
in	 many	 natural	 products	 and	 is	 a	 bioactive	 substance	 in	
human	metabolism	[18].	There	are	many	clinical	drugs	being	
used	in	the	different	therapeutic	areas	based	on	the	imidazole	
structure,	 such	 as	 antihistaminic	 (cimetidine),	 anti‐cancer	
(dacarbazine),	 anti‐parasitic	 (metronidazole),	 and	 antihyper‐
tensive	(losartan)	(Figure	1).	
Many	heterocyclic	cores	have	played	significant	role	in	the	
pharmacological	 activities,	 like	 pyridine	 core,	 the	 high	 thera‐
peutic	 properties	 of	 pyridine	 related	 drugs	 have	 encouraged	
medicinal	chemists	to	the	synthesized	large	number	of	chemo‐
therapeutic	 agents.	 The	 medicinal	 properties	 of	 pyridine	




Various	 methods	 for	 the	 synthesis	 of	 multi‐substituted	
imidazole	 derivatives	 involving	 different	 catalysts	 including	
AlCl3,	 FeCl3,	 Yb(OTf)3,	 NdCl3,	 LaCl3	 [27],	 ZrOCl2.8H2O	 [28],	









The	 application	 of	 microwave	 irradiation	 is	 the	 use	 of	
catalysts	 or	 mineral	 supported	 reagents,	 under	 solvent‐free	
conditions,	enables	organic	reactions	to	occur	expeditiously	in	
ambient	 pressure,	 thus	 providing	 unique	 chemical	 processes	







5‐Bromopyridine‐2,	 3‐diamine,	 substituted	 aldehydes,	
N,N‐dimethylformamide,	 glacial	 acetic	 acid	 and	 various	
solvents	 were	 commercially	 available.	 The	 major	 chemicals	
were	 purchased	 from	 Sigma	 Aldrich	 and	 Avra	 labs.	 Reaction	
progress	 was	 monitored	 by	 TLC	 on	 silica	 gel	 precoated	 F254	
Merck	 plates.	 Developed	 plates	 were	 examined	 with	
ultraviolet	lamps	(254	nm).	IR	spectra	were	recorded	on	a	FT‐
IR	 (Bruker).	 Melting	 points	 were	 recorded	 on	 SRS	 Optimelt,	
melting	point	apparatus	and	are	uncorrected.	1H	NMR	spectra	
were	 recorded	 on	 a	 400	 MHz	 Bruker	 spectrometer	 and	 13C	
NMR	 spectra	 were	 recorded	 on	 a	 100	 MHz	 Bruker	
spectrometer	 are	 reported	 as	 parts	 per	 million	 (ppm)	
downfield	 from	 a	 tetramethylsilane	 internal	 standard.	 The	
following	 abbreviations	 are	 used;	 singlet	 (s),	 doublet	 (d),	
triplet	 (t),	 quartet	 (q),	 multiplet	 (m)	 and	 broad	 (br).	 Mass	
spectra	 were	 taken	 with	 Micromass‐QUATTRO‐II	 of	 water	









An	 equimolar	 amounts	 of	 5‐bromopyridine‐2,3‐diamine	
(1)	 (1	 mmol),	 substituted	 aldehydes	 (2a‐l)	 (1	 mmol)	 was	
added	 in	 DMF.	 This	 mixture	 was	 taken	 in	 a	 100	 mL	 round	
bottom	flask	 subjected	 to	MW	 irradiation	 (900	W),	at	110	 °C	
temperature	 for	 5‐6	 min.	 The	 completion	 of	 the	 reaction	
progress	was	monitored	by	using	TLC	(10%,	ethyl	acetate:	n‐
hexane).	 The	 product	 obtained	 was	 poured	 into	 water	 and	
ethyl	 acetate	 (2:8,	 v:v)	 (3×10	 mL).	 The	 combined	 solvent	






An	 equimolar	 amounts	 of	 5‐bromopyridine‐2,	 3‐diamine	
(1)	 (1	 mmol),	 substituted	 aldehydes	 (2a‐l)	 (1	 mmol)	 were	
added	 in	 DMF.	 This	 mixture	 was	 taken	 in	 a	 100	 mL	 round	
bottom	flask	and	stirring	on	reflux	up	to	3‐4	h.	The	completion	
of	 the	 reaction	 progress	was	monitored	 by	 using	 TLC	 (10%,	
ethyl	 acetate:	 n‐hexane).	 The	 product	 obtained	 was	 poured	
into	 water	 and	 ethyl	 acetate	 (2:8,	 v:v)	 (3×10	 mL).	 The	
combined	 solvent	 extracts	 were	 concentrated	 in	 vacuo.	 The	






Aromatic),	 7.62	 (s,	 1H,	 pyridine	 H),	 9.40	 (s,	 1H,	 pyridine	H),	
10.10	 (s,	 1H,	NH).	 13C	NMR	 (100	MHz,	CDCl3,	 δ,	 ppm):	119.2,	





1468	 (C=C),	 825	 (C‐Br).	 1H	 NMR	 (400	 MHz,	 CDCl3,	 δ,	 ppm):	
5.50	 (s,	 1H,	OH),	 6.85‐6.87	 (d,	2H,	H‐Aromatic),	 6.96‐6.98	 (d,	
2H,	H‐Aromatic),	8.45	(s,	1H,	pyridine),	9.40	(s,	1H,	pyridine),	




(3c):	Color:	Yellow	solid.	Yield:	 95%.	M.p.:	 214‐216	 °C.	 FT‐IR	
(KBr,	 ,	 cm‐1):	 3027	 (NH),	 3008	 (aromatic	 CH),	 1578	 (C=N),	
1461	(C=C),	790	(C‐Cl),	688	(C‐Br).	1H	NMR	(400	MHz,	CDCl3,	
δ,	ppm):	7.70‐8.00	(m,	3H,	H‐Aromatic),	8.10	(s,	1H,	pyridine),	






631	 (C‐Br).	 1H	NMR	 (400	MHz,	 CDCl3,	 δ,	 ppm):	 7.50‐7.52	 (d,	
2H,	 H‐Aromatic),	 7.68‐7.70	 (d,	 2H,	 H‐Aromatic),	 7.95	 (s,	 1H,	
pyridine),	 8.15	 (s,	 1H,	 pyridine),	 8.80	 (s,	 1H,	 NH).	 13C	 NMR	














637	 (C‐Br).	 1H	NMR	 (400	MHz,	 CDCl3,	 δ,	 ppm):	 7.60‐7.86	 (m,	
4H,	H‐Aromatic),	8.20	(s,	1H,	pyridine),	8.50	(s,	1H,	pyridine),	
9.15	 (s,	 1H,	 NH).	 13C	 NMR	 (100	 MHz,	 CDCl3,	 δ,	 ppm):	 119.1,	
127.5,	 128.4,	 129.5,	 130.1,	 131.7,	 132.4,	 134.7,	 138.5,	 147.5,	
148.0,	150.5.	MS	(EI,	m/z	(%)):	308.85.	
6‐Bromo‐2‐(4‐methoxyphenyl)‐3H‐imidazo[4,	 5‐b]pyridine	
(3f):	 Color:	 Yellow	 solid.	 Yield:	 95%.	M.p.:	 191‐193	 °C.	 FT‐IR	
(KBr,	 ,	 cm‐1):	 3198	 (NH),	 3006	 (aromatic	 CH),	 1553	 (C=N),	
1461	 (C=C),	 634	 (C‐Br).	 1H	 NMR	 (400	 MHz,	 CDCl3,	 δ,	 ppm):	
3.75	(s,	3H,	OCH3),	7.05‐7.26	(m,	4H,	H‐Aromatic),	8.54	(s,	1H,	
pyridine),	 9.14	 (s,	 1H,	 pyridine),	 10.76	 (s,	 1H,	 NH).	 13C	 NMR	
(100	 MHz,	 CDCl3,	 δ,	 ppm):	 55.9,	 114.8,	 119.1,	 127.4,	 130.3,	





1451	 (C=C),	 638	 (C‐Br).	 1H	 NMR	 (400	 MHz,	 CDCl3,	 δ,	 ppm):	
3.76	(s,	6H,	OCH3),	7.15‐7.46	(m,	3H,	H‐Aromatic),	8.52	(s,	1H,	






(KBr,	 ,	 cm‐1):	 3219	 (NH),	 3051	 (aromatic	 CH),	 1590	 (C=N),	
1463	(C=C),	904	(C‐F),	640	(C‐Br).	1H	NMR	(400	MHz,	CDCl3,	δ,	
ppm):	 7.43‐7.78	 (m,	 4H,	 H‐Aromatic),	 8.51	 (s,	 1H,	 pyridine),	




(3i):	 Color:	 Yellow	 solid.	 Yield:	 94%.	 M.p.:147‐149	 °C.	 FT‐IR	
(KBr,	 ,	 cm‐1):	 3218	 (NH),	 3053	 (aromatic	 CH),	 1577	 (C=N),	
1457	(C=C),	965	(C‐F),	674	(C‐Br).	1H	NMR	(400	MHz,	CDCl3,	δ,	
ppm):	 7.33‐7.79	 (m,	 4H,	 H‐Aromatic),	 8.55	 (s,	 1H,	 pyridine),	





cm‐1):	 3228	 (NH),	 3033	 (aromatic	 CH),	 1513	 (C=N),	 1469	
(C=C),	 1339	 (NO2),	 686	 (C‐Br).	 1H	 NMR	 (400	MHz,	 CDCl3,	 δ,	
ppm):	8.03	(m,	4H,	H‐Aromatic),	8.58	(s,	1H,	pyridine),	9.06	(s,	
1H,	pyridine),	10.79	(s,	1H,	NH).	 13C	NMR	(100	MHz,	CDCl3,	δ,	




(KBr,	 ,	 cm‐1):	 3226	 (NH),	 3022	 (aromatic	 CH),	 2224	 (CN),	
1569	(C=N),	1464	(C=C),	624	(C‐Br).	1H	NMR	(400	MHz,	CDCl3,	
δ,	ppm):	7.53‐7.79	(m,	4H,	H‐Aromatic),	8.54	(s,	1H,	pyridine),	





cm‐1):	 3224	 (NH),	 3065	 (aromatic	 CH),	 1594	 (C=N),	 1457	
(C=C),	702	(C‐Br).	1H	NMR	(400	MHz,	CDCl3,	δ,	ppm):	7.35‐7.72	
(m,	 3H,	 H‐Aromatic),	 8.53	 (s,	 1H,	 pyridine),	 9.12	 (s,	 1H,	
pyridine),	 10.86	 (s,	 1H,	 NH).	 13C	 NMR	 (100	 MHz,	 CDCl3,	 δ,	







All	 the	 synthesized	 compounds	 (3a‐l)	 were	 screened	 for	
their	 in	 vitro	 antibacterial	 activity;	 three	 Gram	 positive	
bacteria;	 Bacillus	 subtilis	 (NCIM‐2063),	 Enterococcus	 faecalis	
(NCIM‐5443)	 and	 Staphylococcus	 aureus	 (NCIM‐2901),	 three	
Gram	 negative	 bacteria;	 Escherichia	 coli	 (NCIM‐2256),	
Pseudomonas	 aeruginosa	 (NCIM‐2037)	 and	 Salmonella	
typhimurium	(NCIM‐2501).	The	organisms	were	obtained	from	
the	 National	 Chemical	 Laboratory,	 Pune,	 MS,	 India.	 The	
antibacterial	assay	was	carried	out	by	a	microdilution	method	
[35‐37]	 in	 order	 to	 determine	 the	 antibacterial	 activity	 of	
compounds	tested	against	the	human	pathogenic	bacteria.	The	
bacterial	 suspensions	 were	 adjusted	 with	 sterile	 saline	 to	 a	
concentration	of	1.0	×	105	CFU/mL.	The	inocula	were	prepared	
daily	and	stored	at	+4	°C	until	use.	The	dilutions	of	the	inocula	
were	 cultured	 on	 solid	 medium	 to	 verify	 the	 absence	 of	






All	 the	 synthesized	 compounds	 (3a‐l)	 were	 screened	 for	
their	 in	 vitro	 antifungal	 activity.	 Six	 fungal	 strains;	 Candida	













°C	 for	 further	 use.	 Dilutions	 of	 the	 inocula	were	 cultured	 on	
solid	malt	agar	 to	verify	 the	absence	of	contamination	and	to	
check	the	validity	of	the	inoculum.		
The	Minimum	 inhibitory	 concentration	 (MIC)	 determina‐
tions	were	performed	by	a	serial	dilution	technique	using	96‐
well	 microtiter	 plates.	 The	 compounds	 investigated	 were	
dissolved	 in	 5%	 DMSO	 solution	 containing	 0.1%	 Tween	 80	









The	 microplates	 were	 incubated	 at	 Rotary	 shaker	 (160	
rpm)	 for	 72	 h	 at	 28	 °C.	 The	 lowest	 concentrations	 without	
visible	growth	(at	 the	binocular	microscope)	were	defined	as	
MICs.	The	 fungicidal	concentrations	 (MFCs)	were	determined	
by	 serial	 sub‐cultivation	 of	 a	 2	 µL	 of	 tested	 compounds	
dissolved	 in	medium	and	 inoculated	 for	 72	h,	 into	microtiter	
plates	 containing	 100	 µL	 of	 broth	 per	 well	 and	 further	
incubation	 72	 h	 at	 28	 °C.	 The	 lowest	 concentration	 with	 no	
visible	growth	was	defined	as	MFC	indicating	99.5%	killing	of	
the	 original	 inoculum.	 The	 DMSO	 was	 used	 as	 a	 negative	
control,	 commercial	 fungicides;	 fluconazole	 and	 miconazole	





The	 minimum	 inhibitory	 and	 bactericidal	 concentrations	
(MICs	 and	 MBCs)	 were	 determined	 using	 96‐well	 microtiter	
plates.	 The	 bacterial	 suspension	 was	 adjusted	 with	 sterile	
saline	to	a	concentration	of	1.0	×	105	CFU/mL.	The	compounds	
to	 be	 investigated	 were	 dissolved	 in	 5%	 DMSO	 solution	
containing	 0.1%	 Tween	 80	 (v:v)	 (1	 mg/mL)	 and	 added	 in	
broth	LB	medium	(100	µL)	with	bacterial	inoculum	(1.0	×	104	
CFU	 per	 well)	 to	 achieve	 the	 wanted	 concentrations.	 The	
micro‐plates	were	 incubated	 at	 Rotary	 shaker	 (160	 rpm)	 for	
24	 h	 at	 48	 °C.	 The	 lowest	 concentrations	 without	 visible	
growth	 (at	 the	 binocular	 microscope)	 were	 defined	 as	




no	 visible	 growth	was	 defined	 as	 the	MBC,	 indicating	 99.5%	
killing	 of	 the	 original	 inoculum.	 The	 optical	 density	 of	 each	
well	was	measured	at	a	wavelength	of	655	nm	by	Microplate	
manager	 4.0	 and	 compared	 with	 a	 blank	 and	 the	 positive	
control.	 The	 ciprofloxacin	 and	 ampicillin	 were	 used	 as	 a	






All	 the	 synthesized	compounds	were	also	 tested	 for	 their	
in	 vitro	 anticancer	 activity	 against	 two	 human	 breast	 cancer	
cell	 lines	 MCF‐7	 and	 BT‐474.	 The	 anticancer	 activity	 test	 is	
performed	 according	 to	 the	 procedure	 developed	 by	 the	
National	Cancer	Institute	(NCI,	USA)	in	the	‘In	vitro	Anticancer	
Drug	 Discovery	 Screen’	 that	 uses	 the	 protein‐binding	 dye	
Sulforhodamine	B	(SRB)	to	assess	cell	growth	[39,40].	Briefly,	
cells	are	grown	in	96‐well	plates	in	suspension	and	then	were	
exposed	 for	 48	 hours	 to	 four	 serial	 concentrations	 of	 10‐7	
Molar	 (M),	 10‐6	 M,	 10‐5	 M	 and	 10‐4	 M	 of	 each	 compound.	
Following	 this,	 cells	 were	 fixed	 and	 stained	 with	 protein	
binding	SRB	stain.	Excess	stain	is	washed	and	bound	stain	was	
solubilized,	and	the	absorbance	was	measured	at	492	nm	in	a	
plate	 reader.	 Concentration	 of	 the	 compounds	 that	 inhibited	
50%	 of	 the	 net	 cell	 growth,	 growth	 inhibition	 of	 50%	 (GI50),	
was	calculated	from	the	dose	response	curve	obtained	for	each	
test	 compound	 and	 cell	 line.	 GI50	 values	 were	 presented	 in	
micro	 molar	 (μM)	 concentration.	 Adriamycin	 (Doxorubicin)	
was	used	as	positive	control	for	the	comparison	of	cytotoxicity	
of	 synthesized	 compounds.	 Assays	 were	 performed	 in	







We	 have	 developed	 the	 protocol	 for	 the	 synthesis	 of	 6‐
bromo‐2‐phenyl‐3H‐imidazo[4,5‐b]pyridine	(3)	(Scheme	1)	by	
condensation	 between	 5‐bromopyridine‐2,3‐diamine	 and	
benzaldehyde.	In	this	reaction,	various	solvents	were	selected	
as	 a	 model	 reaction	 to	 optimize	 the	 reaction	 conditions.	 In	
terms	 of	 the	 effect	 of	 solvent	 on	 the	 condensation	 reaction,	
DMF	was	found	to	be	the	best	solvent	for	the	reaction	(Table	1,	
entry	4);	other	solvents,	including	ethanol,	methanol,	benzene,	
toluene	 and	 tetrahydrofuran	 were	 less	 efficient	 (Table	 1,	




low	 before	 further	 optimizations.	 All	 the	 reactions	 were	
carried	 out	 with	 equimolar	 amounts	 of	 each	 compound	 in	 1	
mL	 of	 solvent.	 Among	 these	 reactions	 same	 amounts	 of	 the	




entry	4).	Thus,	we	decided	 to	carry	out	 the	 reactions	 in	DMF	
solvent.	
The	plausible	 reaction	mechanism	 is	 shown	 in	Scheme	2.	
The	 initial	 reaction	 of	 5‐bromopyridine‐2,3‐diamine	 with	
benzaldehyde	produces	imine,	which	at	the	reflux	temperature	
is	 dehydrated	 or	 loss	 of	 water.	 Then	 the	 cyclise	 the	 ring,	
product	are	formed	by	the	loss	of	one	proton.		
In	 continuation	 of	 our	work	 [41‐48],	 on	 the	 synthesis	 of	
bioactive	 compounds,	 we	 have	 synthesized	 some	 imidazole	






Entry	 Solvent	 Time	(h)	 Yield	b	(%)	
1	 Ethanol	 11 30
2	 Methanol	 12 45
3	 Benzene	 10 50
4	 DMF	 3 98
5	 Toluene	 7	 40	





Compound	 Aldehydes	(2a‐l)	 Time	(min) Yield	b %	 M.p	(°C)
MW	c	(min)	 Conv.	d	(h)	 MW	c	 Conv.	d	
3a	 Benzaldehyde	 5 3 99 98	 165‐167
3b	 4‐Hydroxybenzaldehyde	 5 3 96 88	 192‐194
3c	 2,4‐Dichlorobenzaldehyde	 6 4 95 86	 214‐216
3d	 4‐Chlorobenzaldehyde	 6	 3	 96	 90	 137‐139	
3e	 2‐Chlorobenzaldehyde	 6 4 94 90	 157‐159
3f	 4‐Methoxybenzaldehyde	 5	 4	 95	 86	 191‐193	
3g	 2,4‐Dimethoxybenzaldehyde	 5	 3	 93	 85	 196‐198	
3h	 4‐Fluorobenzaldehyde	 6	 4	 93	 90	 270‐272	
3i	 3‐Fluorobenzaldehyde	 6 4 94 86	 147‐149
3j	 4‐Nitrobenzaldehyde	 5 3 94 88	 185‐187
3k	 4‐Formylbenzonitrile	 5 3 92 82	 260‐262
3l	 Thiophene‐2‐carbaldehyde	 6 4 96 90	 160‐162	











series	 of	 new	 6‐bromo‐2‐(substitu‐ted)‐3H‐imidazo[4,5‐
b]pyridine	 derivatives,	which	 have	 different	 pharmacological	
active	groups,	which	can	exhibit	anticancer	and	antimicrobial	
activity.	 We	 have	 successfully	 synthesized	 series	 of	 new	 6‐
bromo‐2‐(substituted)‐3H‐imidazo[4,5‐b]pyridine	 (3a‐l)	
(Scheme	 3)	 by	 using	 N,N‐dimethylformamide	 (DMF)	 as	 a	
solvent	 with	 glacial	 acetic	 acid	 in	 catalytic	 amounts,	 under	
microwave‐assisted	technique	as	well	as	conventional	method.	
All	 the	 synthesized	 compounds	 are	 tested	 for	 their	 in	 vitro	
antimicrobial	 activities	 against	 selected	 bacterial	 and	 fungal	
strains	 as	 well	 as	 for	 anticancer	 against	 MCF‐7	 and	 BT‐474	
human	breast	cancer	cell	line.	
Our	 current	 investigation	 describes	 the	 convenient	
synthesis	 of	 new	 6‐bromo‐2‐(substituted)‐3H‐imidazo[4,5‐
b]pyridine	 (3a‐l)	 (Scheme	 3)	 using	 DMF	 as	 a	 solvent	 under	
microwave	 assisted	 as	 well	 as	 conventional	 synthesis	 with	
high	yield	in	a	short	time	period.	This	method	is	unique,	rapid	
and	 convenient	 for	 the	 synthesis	 3H‐imidazo[4,5‐b]pyridine	
derivatives.	We	herein	 report,	 the	 synthesis	 and	 screening	of	
anticancer	and	antimicrobial	activity	of	this	series.	Microwave	
used	 in	 the	 study	 was	 MicroSYNTH	 Lab	 station	 of	 Ethusi	
Milestone	with	 temperature	control	 (Scheme	3,	method	A).	A	
one‐pot,	microwave	assisted	as	well	as	conventional	synthesis	
by	 using	 a	 5‐bromopyridine‐2,3‐diamine,	 substituted	 alde‐
hydes	 and	 DMF	 as	 a	 solvent	 to	 give	 the	 compounds	 (3a‐l)	
(Table	2).	These	 compounds	were	 characterized	on	 the	basis	
of	 spectral	 analysis.	 The	 IR	 spectrum	 of	 representative	
compound	6‐bromo‐2‐phenyl‐3H‐imidazo[4,5‐b]pyridine	(3a),	
IR	absorption	bands	in	the	wave	numbers	show	3065	cm‐1	that	
is	due	 to	 a	 secondary	 amine	 group,	 702	cm‐1	 that	 is	due	 to	 a	




ppm	6.60‐6.95	 (m,	 5H)	 and	 7.62	 (s,	 1H,	 pyridine	H),	 9.40	 (s,	
1H,	 pyridine	 H),	 10.10	 (s,	 1H,	 NH).	 The	 synthesized	 com‐







From	 the	 antimicrobial	 data	 it	 is	 clearly	 observed	 that	
many	 of	 the	 synthesized	 compounds	were	 shows	 prominent	
antimicrobial	 activity	 (Table	 3	 and	 4).	 Antimicrobial	 data	
indicate	 that	 among	 the	 twelve	 synthesis	 compounds	 of	
present	series	many	shows	promising	good	to	moderate	level	
of	 antimicrobial	 activity.	 Some	 compounds	 were	 narrow	
spectrum,	 active	 against	 only	 one	 fungal	 or	 bacterial	 strain	
while	 some	 of	 them	 were	 found	 to	 be	 broad	 spectrum	







B.	subtilis	 S.	aureus E.	coli E.	faecalis P.	aeruginosa	 S.	typhimurium
3a	 MIC	 85	 95	 80 80 90 75	
MBC	 100	 115	 100 95 110 95	
3b	 MIC	 70	 55	 3.25 60 75 70	
MBC	 92	 85	 55	 90	 95	 100	
3c	 MIC	 30	 60	 55	 70	 85	 90	
MBC	 60	 85	 70 95 100 115	
3d	 MIC	 15	 55	 10	 20	 10	 60	
MBC	 45	 80	 35	 55	 30	 100	
3e	 MIC	 20	 65	 15 70 80 75	
MBC	 60	 90	 30 100 110 100	
3f	 MIC	 25	 95	 20 20 90 25	
MBC	 60	 115	 70 45 120 60	
3g	 MIC	 90	 100	 75 100 95 85	
MBC	 110	 120	 95 120 110 100	
3h	 MIC	 55	 70	 80 65 75 60	
MBC	 70	 100	 110	 90	 95	 100	
3i	 MIC	 80	 70	 90	 95	 85	 90	
MBC	 100	 90	 120	 120	 100	 115	
3j	 MIC	 70	 50	 60 65 70 65	
MBC	 95	 85	 90 90 95 100	
3k	 MIC	 6.0	 60	 75 95 80 70	
MBC	 50	 85	 95 90 100 110	
3l	 MIC	 90	 100	 75 80 85 90	
MBC	 120	 120	 100 115 115 110	
Ciprofloxacin	 MIC	 6.25	 6.25	 4.0 6.25 6.25 4.0	
MBC	 20	 20	 20	 20	 20	 20	
Ampicillin	 MIC	 12.5	 12.5	 12.5	 12.5	 12.5	 12.5	





A.	oryzae	 P.	chrysogenum F.	oxysporum C.	albicans A.	flavus	 A.	niger
3a	 MIC	 95	 80	 85	 95	 100	 90	
MFC	 130	 105	 110	 100	 115	 120	
3b	 MIC	 65	 85	 70	 60	 85	 90	
MFC	 90	 115	 100 95 100 130	
3c	 MIC	 75	 100	 90 60 90 80	
MFC	 95	 130	 125 100 115 95	
3d	 MIC	 90	 70	 85 70 80 95	
MFC	 115	 100	 115 105 110 115	
3e	 MIC	 85	 90	 100 20 85 90	
MFC	 100	 115	 130	 60	 110	 120	
3f	 MIC	 30	 100	 95	 90	 30	 35	
MFC	 60	 125	 125	 110	 70	 65	
3g	 MIC	 100	 80	 85 90 85 90	
MFC	 120	 115	 105	 130	 100	 115	
3h	 MIC	 95	 85	 90 65 85 90	
MFC	 115	 120	 105 95 100 125	
3i	 MIC	 95	 80	 90 85 95 100	
MFC	 130	 100	 115 100 130 115	
3j	 MIC	 95	 90	 100 70 80 75	
MFC	 120	 105	 130 95 100 95	
3k	 MIC	 70	 65	 75	 70	 90	 80	
MFC	 115	 90	 100 95 130 125	
3l	 MIC	 95	 90	 100	 80	 85	 90	
MFC	 115	 130	 125	 105	 100	 120	
Fluconazole	 MIC	 6.25	 10	 6.25 10 6.25 6.25	
MFC	 55	 50	 45 40 50 40	
Miconazole	 MIC	 3.25	 3.25 3.25 3.25 3.25 3.25	











against	 one	 or	 more	 bacterial	 as	 well	 as	 fungal	 strains.	









activity	profile	 of	 the	 compound	3e	but	with	 somewhat	high	
MIC	 values.	 However,	 the	 compound	3d	 is	 bacterial	 specific,	
active	 agaist	 the	 four	bacterial	 strains,	B.	 subtilis	 (MIC	15),	E.	
faecalis	(MIC	20),	E.	Coli	(MIC	10)	and	P.	aeruginosa	(MIC	10).	
Remaining	compounds	of	the	series	3a,	3g,	3i	and	3l	are	found	
to	 be	 biologically	 inactive	 in	 nature	 owing	 to	 their	 high	MIC	









Compounds	 (IC50)	a	µMolar	b	 	 Compounds	 (IC50)	a	µMolar	b	
MCF‐7	c	 BT‐474	d MCF‐7	c BT‐474	d	
3a	 68.8	 56.8	 	 3g	 88.4	 68.5	
3b	 65.7	 41.0	 	 3h	 1.7	 0.9	
3c	 64.8	 48.4	 3i 82.2 87.1	
3d	 59.5	 56.2	 3j 1.3 1.1	
3e	 59.7	 57.6	 3k 75.7 66.5	
3f	 80.5	 48.6	 3l 81.1 81.2	










3h	 and	3j	 shows	 prominent	 anticancer	 activity	 against	 both	
cell	lines,	having	Growth	inhibition	of	50	(GI50)	values	of	0.9	to	




any	 substitution,	 at	 C2	 position	 on	 imidazole	 ring	 (3a),	 in	 6‐
bromo‐2‐(substituted)‐3H‐imidazo[4,5‐b]pyridine	 moiety	 is	




at	 the	 para	 position	 on	 the	 phenyl	 ring	 (3b),	 in	 6‐bromo‐2‐
(substituted)	 ‐3H‐imidazo	 [4,5‐b]	 pyridine	 moiety,	 make	 the	
molecule	narrow	spectrum	and	active	only	against	bacterium	
E.	coli.	




Effect	of	chloro	group:	 Introduction	of	 the	chloro	group	 in	
the	 para	 position	 (3d)	 on	 the	 phenyl	 ring	 make	 a	 molecule	
bacterial	 specific;	 active	 towards	 B.	 subtilis	 E.	 faecalis,	 P.	
aeruginosa	 and	 E.	 coli.	 On	 the	 other	 hand,	 changing	 the	
position	of	 this	 group	 from	para	 to	ortho	 (3e)	 on	 the	phenyl	
ring	 make	 the	 molecule	 also	 active	 towards	 the	 fungus	 C.	
albicans	 along	with	 its	antibacterial	properties.	This	 indicates	
that	changing	the	position	of	the	chloro	group	on	phenyl	ring,	
from	 para	 to	 ortho,	 also	 changes	 its	 antimicrobial	 activity	
profile,	 and	 this	 change	 is	 favorable	 for	 the	 development	 of	
antimicrobial	 active	 molecules	 by	 incorporating	 bromo‐2‐
(substituted)‐3H‐imidazo[4,5‐b]pyridine	 moiety.	 However,	
interestingly	simultaneous	presents	of	the	chloro	group	in	the	
ortho	 and	 para	 position	 on	 the	 phenyl	 ring	 (3c)	 make	 the	
molecule	inactive	in	nature.	This	may	happen	due	to	increase	
the	 size	 of	 molecules	 as	 well	 as	 the	 steric	 crowding	 effect	
imposed	 by	 two	 chloro	 groups,	 inhibiting	 the	 binding	 of	
molecules	to	its	target	in	biological	system.	
The	 effect	 of	 methoxy	 group:	 Introduction	 of	 methoxy	
group	on	 the	phenyl	 ring	at	 the	para	position	 (3f)	makes	 the	
molecule	broad	spectrum;	active	against	most	of	the	bacterial	
and	 fungal	 strains	 tested.	On	 the	 other	 hand	 simultaneously	
substitution	of	methoxy	group	at	ortho	and	para	position	(3g)	






position	 on	 the	 phenyl	 ring	 (3h)	 gives	 the	 potent	 anticancer	
molecule,	 inhibiting	 the	 growth	 of	 breast	 cancer	 cell	 lines,	
MCF7	and	BT‐474,	in‐vitro.		
Effect	of	nitro	group:	The	substitution	of	the	Nitro	group	at	




2‐yl	 group	 at	 2‐position	 on	 imidazole	 moiety	 (3l),	 shows	





In	 conclusion,	 the	 compounds	 were	 synthesized	 by	
microwave‐irradiations	as	well	as	conventional	methods	with	
reduced	 reaction	 times	 and	 increased	 yields	 of	 the	 products.	
Among	 the	 synthesized	 compounds,	 3h	 and	 3j	 shows	
prominent	 anticancer	 activity	 against	 both	 breast	 cancer	 cell	
lines,	MCF‐7	and	BT‐474.	While	the	compounds	3b	and	3k	are	
specifically	 active	 towards	 bacterium	 E.	 coli	 and	 B.	 subtilis,	
respectively;	more	potent	than	standard	drugs	used.	It	should	
be	 noticed	 that	 some	 compounds	 tested	 exhibited	 better	
activity	 than	 commercial	 antimicrobial	 agents	 used	 as	
reference	drugs	while	there	were	less	active	than	ciprofloxacin	
and	ampicillin.	The	some	of	the	compounds	showed	the	worst	







Aurangabad	 431004,	 India,	 for	 providing	 the	 laboratory	
facility.	The	authors	are	also	thankful	to	the	Advanced	Centre	
























[11]. Sharma,	 D.;	 Narasimhan,	 B.;	 Kumar,	 P.;	 Judge,	 V.;	 Narang,	 R.;	 De	
Clercq,	E.;	Balzarini,	J.	Eur.	J.	Med.	Chem.	2009,	44,	2347‐2353.		








[16]. Hranjec,	 M.;	 Starcevic,	 K.;	 Piantanida,	 I.;	 Kralj,	 M.;	 Marjanovic,	 M.;	
Hasani,	 M.;	 Westman,	 G.;	 Karminski‐Zamola,	 G.	 Eur.	 J.	 Med.	 Chem.	
2008,	43,	2877‐2890.		
[17]. Martinez,	V.;	Burgos,	V.;	Alvarez‐Builla,	J.;	Fernandez,	G.;	Domingo,	A.;	
Garcia‐Nieto,	R.;	Gago,	F.;	Manzanares,	 I.;	Cuevas,	C.;	Vaquero,	 J.	 J.	 J.	
Med.	Chem.	2004,	47,	1136‐1148.		




[20]. Fortuna,	 G.	 C.;	 Barresi,	 V.;	 Berellini,	 G.;	Musumarra,	 G.	Bioorg.	Med.	
Chem.	2008,	16,	4150‐4169.		
[21]. Nicolaou,	K.	C.;	Scarpelli,	R.;	Bollbuck,	B.;	Werschkun,	B.;	Pereira,	M.	
M.	 M.;	 Wartmann,	 M.;	 Altmann,	 K.	 H.;	 Zaharevitz,	 D.;	 Gussio,	 R.;	
Giannakakou,	P.	Chem.	Biol.	2000,	7,	593‐599.		




[24]. Banie,	H.;	Sinha,	A.;	Thomas,	R.	 J.;	Sircar,	 J.	C.;	Richards,	M.	L.	J.	Med.	
Chem.	2007,	50,	5984‐5993.		
[25]. Mader,	M.;	de	Dios,	A.;	Shih,	C.;	Bonjouklian,	R.;	Li,	T.;	White,	W.;	de	
Uralde,	 B.	 L.;	 Sanchez‐Martinez,	 C.;	 del	 Prado,	 M.;	 Jaramillo,	 C.;	 de	
Diego,	 E.;	 Martin	 Cabrejas,	 L.	 M.;	 Dominguez,	 C.;	 Montero,	 C.;	





W.;	 Reiss,	 D.;	 Chang,	 R.	 S.	 L.;	 Harrell,	 C.	 M.;	 MacNeil,	 T.;	 Tang,	 C.;	















[36]. Daouk,	 K.	 D.;	 Dagher,	 M.	 S.;	 Sattout,	 J.	 E.	 J.	 Food	 Protect.	1995,	 58,	
1147.		
[37]. Booth,	 C.;	 Fungal	 Culture	 Media,	 In	 Methods	 in	 Microbiology,	 J.	 R.	
Norris,	D.	W.	Ribbons,	Eds.;	Academic	Press:	London	and	New	York,	
1971;	pp	49‐94.		
[38]. Espinel‐Ingroff,	A.	J.	Clin.	Microbiol.	2001,	39,	1360.		
[39]. Skehan,	P.;	Storeng,	R.;	Scudiero,	D.;	Monks,	A.;	McMahon,	J.;	Vistica,	
D.;	 Jonathan,	T.	W.;	Heidi,	B.;	Susan,	K.;	Michael,	R.	B.;	 J.	Natl.	Cancer	
Inst.	1990,	82,	1107‐1112.		
[40]. Vichai,	V.;	Kirtikara,	K.	Nat.	Proto.	2006,	1,	1112‐1116.		
[41]. Pansare,	D.	N.;	Mulla,	N.	A.;	Pawar,	C.	D.;	Shende,	V.	R.;	Shinde,	D.	B.	
Bioorg.	Med.	Chem.	Lett.	2014,	24,	3569‐3573.		
[42]. Darandale,	S.	N.;	Pansare,	D.	N.;	Mulla,	N.	A.;	Shinde,	D.	B.	Bioorg.	Med.	
Chem.	Lett.	2013,	23,	2632‐2635.		
[43]. Darandale,	S.	N.;	Mulla,	N.	A.;	Pansare,	D.	N.;	Sangshetti,	J.	N.;	Shinde,	
D.	B.	Eur.	J.	Med.	Chem.	2013,	65,	527‐532.		
[44]. Pansare,	D.	N.;	Shinde,	D.	B.	Tetrahedron	Lett.	2014,	55,	1107‐1110.		
[45]. Pansare,	D.	N.;	Shinde,	D.	B.	Open	Chem.	J.	2015,	2,	40‐46;		
[46]. Pawar,	C.	D.;	Sarkate,	A.	P.;	Karnik,	K.	S.;	Bahekar,	S.	S.;	Pansare,	D.	N.;	
Shelke,	R.	N.;	Jawale,	C.	S.;	Shinde,	D.	B.	Bioorg.	Med.	Chem.	Lett.	2016,	
26,	3525‐3528.		
[47]. Pansare,	D.	N.;	Shinde,	D.	B.	Res.	Rev.	J.	Chem.	2015,	4	(1),	8‐14.		
[48]. Shelke,	R.	N.;	Pansare,	D.	N.;	Pawar,	C.	D.;	Shinde,	D.	B.;	Thore,	S.	N.;	
Pawar,	R.	P;	Bembalkar,	S.	R.	Res.	Rev.	J.	Chem.	2016,	5(2),	29‐36.		
	
	
